Astrocytoma, IDH-mutant, grade 4
MONDO:0956981An IDH-mutant anaplastic astrocytoma that is characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas.
2849 clinical trials for this condition and its sub-types, 22 tagged with Astrocytoma, IDH-mutant, grade 4 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug combo aims to fight returning brain tumors
Disease control Not yet recruitingThis early-stage trial tests a new drug called STAR-001 combined with the blood pressure medication spironolactone in about 68 people whose glioblastoma has returned after initial treatment. The goal is to see if the combination is safe and can shrink tumors. Participants receive…
Phase 1/2 • Sponsor: Starlight Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for deadly brain cancer? early trial launches
Disease control Not yet recruitingThis early-stage study tests a new drug called FZ-AD005 in 40 people with aggressive brain tumors (high-grade glioma) that have come back or not responded to treatment. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to find the…
Phase 1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC